Michael Cherny

“August, maybe just to dive into a bit more about your bookings commentary. Clearly, that bookings performance in the quarter is really strong. As you think about where that's coming from, how do you see the evolving competitive environment within the biotech world?”

“Maybe if I can just dive in on PharmaDirect and the growth and positioning of the business. Obviously, it's been a standout in the quarter and the year and the acceleration of guidance.”

“Please go ahead. um good afternoon and thanks for taking the question yeah i started to harp on this same topic but this is not the first time obviously we've seen summer seasonality of you as you've alluded to um maybe a bit more than before when you think about the visibility you had at this point last quarter you…”

“Mike, I want to dive a little bit into some of these expenses and whatnot that you discussed relative to the future baseline thought process. A lot of it clearly, as we can hear, is tied towards outperforming a new business.”

“I apologize to come back on it, but I just, in doing some rough math, even if you go to the high end of your North American pharma guidance for the rest of the year, you're at about 6.8%.”